HIV Research for Prevention Conference ANALYSIS | SETHI NCUBE | The 5th HIV Research for Prevention Conference (HIVR4P 2024) ...

Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...

The 5th HIV Research for Prevention Conference (HIVR4P 2024) held in Lima, Peru, marked a significant milestone in the global ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

Natal, alarming gaps between scientific advancements and community behaviour persist. This article explores the critical need ...

which may result in missed HIV diagnoses or a missed opportunity to receive post-exposure prophylaxis, which can reduce the risk of HIV when taken within 72 hours after a possible HIV exposure.

Lenacapavir is a long-acting injectable drug that has proven 100 per cent successful in clinical tests and subsequent human ...

The increasing incidence of sexually transmitted bacterial infections (STIs) is a major public health problem worldwide.

Here are key takeaways. Now, there are many options to prevent HIV and other STIs, including pre-exposure prophylaxis (PrEP) ...

After launching its “Plan First!” program just over a year ago, the Michigan Department of Health and Human Services says the ...

Did you know with a Digital Subscription to Yorkshire Evening Post, you can get unlimited access to the ... and allows people ...